PeptideKey News

$17B Peptide Factory Race: Will Oral Drugs Strand It?

Bachem, CordenPharma, Neuland race to build peptide capacity. The CDMO market hits $17.4B by 2035 — but oral GLP-1s may strand billions in SPPS investment.

This article is part of PeptideKey's evidence-based peptide research library covering 100+ compounds with lab-verified purity data.